著者

江口 里加 加藤 正久 金子 絵里奈 草場 健司 吉川 学 山野 徹 瀬尾 隆 萩原 明人

出版者

公益社団法人 日本薬学会

雑誌

YAKUGAKU ZASSHI (ISSN:00316903)

巻号頁・発行日

vol.135, no.3, pp.501-506, 2015 (Released:2015-03-01)

参考文献数

26

被引用文献数

1

---

Much of the damage to health caused by drugs could be prevented by appropriate care. A well-defined duty of care and further information are required for healthcare professionals. Although there are many litigation cases to use as references, neither the extent of the duty of care nor the obligation to explain medication according to the type of drug prescribed has yet been fully established. Thus, we systematically collected decided cases of adverse drug events, and assessed the degree of the duties of care and information. Specifically, we collected decided cases in which physicians, dentists, pharmacists, nurses, or hospitals had been sued. Data were derived from Bessatsu Jurist Iryo-kago Hanrei Hyakusen, Hanrei Jihou, and Hanrei Times from 1989 to November 2013, and information on precedents in the records of the Supreme Court of Japan from 2001 to November 2013. We analyzed the cases, and assessed the following according to the type of drug: (1) standards and explanations when dealing with drugs that were critical issues in litigation, and (2) the degree of the physician's or pharmacist's duties of care and information. In total, 126 cases were collected. The number of drug categories classified was 27, and 9 were considered of practical importance. After this systematic review, we found a trend in the degree of the required level of care and information on several drugs. With respect to duties of care and information, the gap between the required level and actual practice suggests that healthcare professionals must improve their care and explanations.

著者

金子 絵里奈 高木 博子 家入 一郎 山野 徹 石橋 久 園田 正信

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.48, no.2, pp.96-105, 2022-02-10 (Released:2023-02-10)

参考文献数

10

---

Although several pharmaceutical inquiries made by community pharmacists meet the PreAVOID criteria, the frequency of PreAVOID reports by community pharmacists is lower than that by hospital pharmacists. We aimed to clarify the characteristics of adverse events (AEs) in pharmaceutical inquiries to increase the number of PreAVOID reports and to improve their quality. We identified AEs using MedDRA/J and compared the types of AEs, information source, and drug efficacies between detected and prevented AEs. In this study, detected AEs were defined as AEs leading to pharmaceutical inquiries after the last visit; prevented AEs were defined as AEs leading to pharmaceutical inquiries before dispensing medicine based on patient interviews, medical records, and laboratory data. We evaluated prescriptions for adults against inquiries at a community pharmacy between April 2016 and March 2019. The chi-squared or Fisher’s exact test was used to compare the number of system organ classes (SOCs) between detected and prevented AEs. We identified 57 detected AEs and 121 prevented AEs from 5,545 prescription inquiries. Gastrointestinal disorders (30 AEs) and skin and subcutaneous tissue disorders (30 AEs) were the most common SOCs that showed a significantly higher number of detected than prevented AEs (P = 0.011 and P < 0.001, respectively). Renal disorder (22 AEs) was the second most common SOC that was associated with prevented AEs (P = 0.001). The results can be used to develop strategies to resolve clinical problems at community pharmacies. Our study contributes to an increase in PreAVOID reports through pharmaceutical inquiries.